MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5255-5261

  Wei, Bin ^a   Huang, Qiao Ying ^b   Huang, Shun Rong ^a   Mai, Wei ^a   Zhong, Xiao Gang ^a  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Invasion metastasis; MET; microRNA 34a; Prognosis; Proliferation

Indexed keywords

MICRORNA 34A; SCATTER FACTOR RECEPTOR; MESSENGER RNA; MICRORNA; MIRN34 MICRORNA, HUMAN;

ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FOLLOW UP; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; REVERSE TRANSCRIPTION; STOMACH; STOMACH CANCER; WESTERN BLOTTING; ADULT; AGED; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION; TUMOR STEM CELL ASSAY;

ADULT; AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR STEM CELL ASSAY;

EID: 84940492801     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4110     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64: 252-271, 2014.
3. Khalighinejad N, Hariri H, Behnamfar O, Yousefi A and Momeni A: Adenoviral gene therapy in gastric cancer: A review. World J Gastroenterol 14: 180-184, 2008.
4. Leja M, Wex T and Malfertheiner P: Markers for gastric cancer premalignant lesions: Where do we go? Dig Dis 30: 268-276, 2012.
5. Amedei A, Della Bella C, Silvestri E, Prisco D and D'Elios MM: T cells in gastric cancer: Friends or foes. Clin Dev Immunol 2012: 690571, 2012.
6. Toiyama Y, Okugawa Y and Goel A: Dna methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun 455: 43-57, 2014.
7. Felipe AV, Oliveira J, Chang PY, et al: RNA interference: a promising therapy for gastric cancer. Asian Pac J Cancer Prev 15: 5509-5515, 2014.
8. Pasquinelli AE: MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13: 271-282, 2012.
9. Wang Y and Lee CG: MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 13: 12-23, 2009.
10. Bueno MJ, Pérez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle 7: 3143-3148, 2008.
11. Liang LH and He XH: Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin 32: 1311-1320, 2011.
12. Lowery AJ, Miller N, McNeill RE and Kerin MJ: MicroRNAs as prognostic indicators and therapeutic targets: Potential effect on breast cancer management. Clin Cancer Res 14: 360-365, 2008.
13. Nouraee N and Calin GA: MicroRNAs as cancer biomarkers. Microrna 2: 102-117, 2013.
14. Berindan-Neagoe I, Monroig Pdel C, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin 64: 311-336, 2014.
15. Maroof H, Salajegheh A, Smith RA and Lam AK: Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. Exp Mol Pathol 97: 298-304, 2014.
16. Balca-Silva J, Sousa Neves S, Goncalves AC, et al: Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 32: 1603-1609, 2012.
17. Li Y, Guessous F, Zhang Y, et al: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576, 2009.
18. Cao W, Fan R, Wang L, et al: Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol 34: 963-971, 2013.
19. Dang Y, Luo D, Rong M and Chen G: Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One 8: e61054, 2013.
20. Pineau P, Volinia S, McJunkin K, et al: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 107: 264-269, 2010.
21. Yao Y, Suo AL, Li ZF, et al: MicroRNA profling of human gastric cancer. Mol Med Rep 2: 963-970, 2009.
22. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL and Dobbelstein M: p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68: 10094-10104, 2008.
23. Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.
24. Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBio-Portal. Sci Signal 6: p11, 2013.
25. Camp RL, Dolled-Filhart M and Rimm DL: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10: 7252-7259, 2004.
26. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
27. Zhang L, Huang J, Yang N, et al: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 13: 9136-9141, 2006.
28. Hsu SD, Lin FM, Wu WY, et al: miRTarBase: A database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 39: D163-D169, 2011.
29. Calin GA, Ferracin M, Cimmino A, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
30. Parrella P, Barbano R, Pasculli B, et al: Evaluation of microRNA-10b prognostic signifcance in a prospective cohort of breast cancer patients. Mol Cancer 13: 142, 2014.
31. Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S and Kristensen BW: MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111: 71-81, 2013.
32. Tu Y, Gao X, Li G, et al: MicroRNA-218 inhibits glioma invasion, migration, proliferation and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 73: 6046-6055, 2013.
33. Aqeilan RI, Calin GA and Croce CM: miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 17: 215-220, 2010.
34. Bonci D, Coppola V, Musumeci M, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277, 2008.
35. Houbaviy HB, Murray MF and Sharp PA: Embryonic stem cell-specifc MicroRNAs. Dev Cell 5: 351-358, 2003.
36. Dostie J, Mourelatos Z, Yang M, Sharma A and Dreyfuss G: Numerous microRNPs in neuronal cells containing novel microRNAs. RNA 9: 180-186, 2003.
37. Lim L P, Glasner ME, Yekta S, Burge CB and Bartel DP: Vertebrate microRNA genes. Science 299: 1540, 2003.
38. He L, He X, Lim L P, et al: A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134, 2007.
39. Cho WC: OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer 6: 60, 2007.
40. Lutterbach B, Zeng Q, Davis LJ, et al: Lung cancer cell lines harboring MET gene amplifcation are dependent on Met for growth and survival. Cancer Res 67: 2081-2088, 2007.
41. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplif-cation leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
42. Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480-1488, 2003.
43. Sawada K, Radjabi AR, Shinomiya N, et al: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1679, 2007.
44. Kammula US, Kuntz EJ, Francone TD, et al: Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248: 219-228, 2007.